Journal of Neurology

, Volume 243, Issue 5, pp 410–416 | Cite as

Prednisone can protect against exercise-induced muscle damage

  • S. C. J. M. Jacobs
  • A. L. Bootsma
  • P. W. A. Willems
  • P. R. Bär
  • J. H. J. Wokke
Original Communication


In an experimental animal exercise model we tested whether daily administration of prednisone prevents the development of mechanically induced muscle fibre damage. Six-week-old rats were treated with different doses of prednisone ranging from 1 to 50 mg/kg body weight per day or with placebo, for 8 days. On day 6 of treatment the rats were forced to run for 2 h on a level treadmill. Two days after exercise morphological damage in the soleus muscles was quantified using light microscopy and a semi-automatic image analysis system. Creatine kinase (CK) activity was measured before exercise (day 5) and directly after exercise (day 6). The expression of dystrophin in a placebo group and in a group that received 5 mg prednisone/kg body weight per day with and without performing exercise was studied with Western blotting. The effect of prednisone on fibre type distribution was determined with an antibody against fast myosin and the effect of prednisone on the proliferative activity of muscle satellite cells was studied using bromodeoxyuridine (BrdU) immunohistochemistry. Exercise-induced muscle fibre damage varied in a dose-dependent way. In the placebo group the mean (SEM) damaged muscle fibre area was 4% (1%). The groups that received low doses of prednisone, 1 or 2.5 mg/kg per day, showed a similar level of muscle damage. However, with 5 mg prednisone/kg per day the amount of muscle fibre damage [mean (SEM)] was significantly reduced to 1.4% (0.5%) (P ≤ 0.05, Student'st-test). High doses of prednisone had no protective effect. Directly after exercise the CK activity was increased two-fold, except in the group that received 50 mg prednisone/kg body weight per day. No changes in the amount of dystrophin were found after densitometric analysis of the Western blots. Prednisone did not affect the fibre distribution or the labelling index of satellite cells. We conclude that prednisone, given in an appropriate dose, protects muscle fibres against the development of mechanically induced damage, possibly by stabilizing the muscle fibre membranes. This action may explain the beneficial effect of prednisone observed in Duchenne muscular dystrophy patients.

Key words

Prednisone Exercise Muscle damage Dystrophin Creatine kinase activity 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Adams JC (1981) Heavy metal intensification of DAB-based HRP reaction products. J Histochem Cytochem 29:775–780PubMedGoogle Scholar
  2. 2.
    Amelink HGJ, Bär PR (1986) Exercise-induced muscle damage in the rat. Effects of hormonal manipulation. J Neurol Sci 76:61–68PubMedGoogle Scholar
  3. 3.
    Amelink HGJ, Van der Kallen CJH, Wokke JHJ, Bär PR (1990) Dantrolene sodium diminishes exercise-induced muscle damage in the rat. Eur J Pharmacol 179:187–192PubMedGoogle Scholar
  4. 4.
    Bär PR, Rodenbuzg AJB, Koot RW, Amelink HGJ (1994) Exercise-induced muscle damage: recent developments. Basic Appl Myol 4:5–16Google Scholar
  5. 5.
    Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley RT, Miller JP, Kaiser KK, Florence JM, Pandya S, Signore L, King W, Robinson J, Head RA, Province MA, Seyfried W, Mandel P (1987) Clinical investigation of Duchenne muscular dystrophy: interesting results in a trial of prednisone. Arch Neurol 44:812–817PubMedGoogle Scholar
  6. 6.
    Chang J, Musser JH, McGregor H (1987) Phospholipase A2: function and pharmacological regulation. Biochem Pharmacol 36:2429–2436PubMedGoogle Scholar
  7. 7.
    Cullen MJ, Johnson MA, Mastaglia FL (1992) Pathological reactions of skeletal muscle. In: Mastaglia FL, Lord Walton (eds) Skeletal muscle pathology. Churchill Livingstone, London, pp 123–184Google Scholar
  8. 8.
    Davidson FF, Dennis EA, Powel M, Glenney JR Jr (1987) Inhibition of phospholipase A2 by lipocortins: an effect of binding to phospholipids. J Biol Chem 262:1698–1705PubMedGoogle Scholar
  9. 9.
    Dennis EA, Davidson FF (1990) Phospholipase A2 and Lipocortin effects. In: Meli M, Parente L (eds) Cytokines and lipocortins in inflammation and differentiation. Progress in clinical and biological research, vol 349. Wiley-Liss, New York, pp 47–54Google Scholar
  10. 10.
    Driessen-Kletter MF, Amelink GJ, Bär PR, Van Gijn J (1990) Myoglobin is a sensitive marker of increased muscle membrane vulnerability. J Neurol 237:234–238PubMedGoogle Scholar
  11. 11.
    Duncan CJ (1989) Dystrophin and the integrity of the sarcolemma in Duchenne muscular dystrophy. Experientia 45:175–177PubMedGoogle Scholar
  12. 12.
    Ervasti JM, Ohlendieck K, Kahl SD, Gaver MG, Campbell KP (1990) Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345:315–319PubMedGoogle Scholar
  13. 13.
    Flower RJ (1990) Lipocortin. In: Meli M, Parente L (eds) Cytokines and lipocortins in inflammation and differentiation. Progress in clinical and biological research, vol 349. Wiley-Liss, New York, p 25Google Scholar
  14. 14.
    Flower RJ, Rothwell NJ (1994) Lipocortin-1: cellular mechanism and clinical relevance. Trends Pharmacol Sci 15:71–76PubMedGoogle Scholar
  15. 15.
    Griggs RC, Moxley RT, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, Miller JP and the Clinical Investigation of Duchenne Dystrophy Group (1991) Prednisone in Duchenne dystrophy. A randomized controlled trial defining the time course and dose response. Arch Neurol 48:383–388PubMedGoogle Scholar
  16. 16.
    Griggs RC, Moxley RT, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, Miller JP, Cwik VA, Pandya S, Robinson J, King W, Signore L, Schierbecker J, Florence J, Matheson-Burden N, Wilson B (1993) Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 43:520–527PubMedGoogle Scholar
  17. 17.
    Hardiman O, Sklar RM, Brown RH (1993) Methylprednisolone selectively affects dystrophin expression in human muscle cultures. Neurology 43:342–345PubMedGoogle Scholar
  18. 18.
    Ibraghimov-Breskovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW, Campbell KP (1992) Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 355:696–702PubMedGoogle Scholar
  19. 19.
    Jacobs SCJM, Wokke JHJ, Bär PR, Bootsma AL (1995) Satellite cell activation after muscle damage in young and adult rats. Anat Rec 242:329–336PubMedGoogle Scholar
  20. 20.
    Karpati G, Carpenter SC (1988) The deficiency of a sarcolemmal cytoskeletal protein (dystrophin) leads to necrosis of skeletal muscle fibers in Duchenne-Becker dystrophy. In: Sellin LS, Libellius R, Thesloff S (eds) Neuromuscular junction. Elsevier, Amsterdam, pp 429–436Google Scholar
  21. 21.
    Kelly FJ, McGrath JA, Goldspink DF, Cullen MJ (1986) A morphological/biochemical study on the actions of corticosteroids on rat skeletal muscle. Muscle Nerve 9:1–10Google Scholar
  22. 22.
    Khan MA (1993) Corticosteroid therapy in Duchenne muscular dystrophy. J Neurol Sci 120:8–14PubMedGoogle Scholar
  23. 23.
    Kissel JT, Lynn DJ, Rammohan KW, Klein JP, Griggs RC, Moxley RT, Cwik VA, Brooke MH, Mendell JR (1993) Mononuclear cell analysis of muscle biopsies in prednisone- and azathioprine-treated Duchenne muscular dystrophy. Neurology 43:532–536PubMedGoogle Scholar
  24. 24.
    Komulainen J, Vihko V (1994) Exercise-induced necrotic muscle damage and enzyme release in the four days following prolonged submaximal running in rats. Pflugers Arch 428:3–4Google Scholar
  25. 25.
    Kuipers H, Drukker J, Frederik PM, Geurten P, Van Kranenburg G (1983) Muscle degeneration after exercise in rats. Int J Sports Med 4:45–51PubMedGoogle Scholar
  26. 26.
    Luo VJ, Murphy LJ (1989) Dexamethasone inhibits growth induction of insulin-like growth factor (IGF-I) messenger ribonucleic acid (mRNA) in hypophysectomized rats and reduces IGF-I mRNA abundance in the intact rat. Endocrinology 125:165–171PubMedGoogle Scholar
  27. 27.
    Matsumura K, Campbell KP (1994) Dystrophin-glycoprotein complex: its role in the molecular pathogenesis of muscular dystrophies. Muscle Nerve 17:2–15PubMedGoogle Scholar
  28. 28.
    McLean IW, Nakane PK (1974) Periodate-lysine-paraformaldehyde fixative. A new fixative for immunoelectron microscopy. J Histochem Cytochem 22:1077–1083PubMedGoogle Scholar
  29. 29.
    McNeil PL (1993) Cellular and molecular adaptations to injurious mechanical stress. Trends Cell Biol 3:302–307PubMedGoogle Scholar
  30. 30.
    Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, King W, Signore L, Pandya S, Florence J, Schierbecker J, Robison J, Kaiser K, Mandel S, Arfken G, Gilder B (1989) Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 320:1592–1597PubMedGoogle Scholar
  31. 31.
    Menke A, Jockusch H (1991) Decreased osmotic stability of dystrophinless muscle cells from mdx mouse. Nature 349:9–71Google Scholar
  32. 32.
    Moxley RT, Lorenson M, Griggs RC, Mendell JR, Fenichel GM, Brooke MH, Miller JP, and CIDD group (1990) Decreased breakdown of muscle protein after prednisone therapy in Duchenne dystrophy (DD). J Neurol Sci 98:419Google Scholar
  33. 33.
    Nicholson LVB, Johnson MA, Gardner-Medwin D, Bhattacharya S, Harris JB (1989) Heterogeneity of dystrophin expression in patients with Duchenne and Becker muscular dystrophy. Acta Neuropathol (Berl) 80:239–250Google Scholar
  34. 34.
    Ohlendieck K, Matsumura K, Ionasescu VV, Towbin JA, Bosch EP, Weinstein SL, Sernett SW, Campbell KP (1993) Duchenne muscular dystrophy: deficiency of dystrophin-associated proteins in the sarcolemma. Neurology 43:795–800PubMedGoogle Scholar
  35. 35.
    Paget GE, Barnes JM (1964) Toxicity test. In: Bacharach L (ed) Evaluation of drug activities: pharmacometrics. Academic Press, London, pp 161Google Scholar
  36. 36.
    Pasternak C, Wong S, Elson EL (1992) The mechanical function of dystrophin in muscle cells. Mol Biol Cell 192a: Suppl 192a:1111Google Scholar
  37. 37.
    Sklar RM, Brown RH (1991) Methylprednisolone increases dystrophin levels by inhibiting myotube death during myogenesis of normal human muscle in vitro. J Neurol Sci 101:73–81PubMedGoogle Scholar
  38. 38.
    Turner PR, Westwood T, Regen CM, Steinhardt RA (1989) Increased protein degradation results from elevated free calcium levels found in muscle from MDX mice. Nature 335:735–738Google Scholar
  39. 39.
    Van de Kant HJG, De Rooij DG (1992) Periodic acid incubation can replace hydrochloric acid hydrolysis and trypsin digestion in immunogold-silver staining of bromodeoxyuridine incorporation in plastic sections and allows the PAS reaction. Histochem 124:170–175Google Scholar
  40. 40.
    Van Kuijk FJGM, Sevanian A, Handelman GJ, Dratz EA (1987) A new role for phospholipase A2: protection of membranes from lipid peroxidation damage. Trends Biochem Sci 12:31–34Google Scholar
  41. 41.
    Vane J, Botting R (1987) Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J 1:89–96PubMedGoogle Scholar
  42. 42.
    Weller B, Karpati G, Carpenter S (1990) Dystrophin-deficient mdx muscle fibers are preferentially vulnerable to necrosis induced by experimental lengthening contractions. J Neurol Sci 100:9–13PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • S. C. J. M. Jacobs
    • 1
  • A. L. Bootsma
    • 1
  • P. W. A. Willems
    • 2
  • P. R. Bär
    • 2
  • J. H. J. Wokke
    • 2
  1. 1.Department of Cell Biology, Medical SchoolUtrecht UniversityUtrechtThe Netherlands
  2. 2.Department of NeurologyUtrecht UniversityUtrechtThe Netherlands

Personalised recommendations